Lebrikizumab Wins FDA Approval for Eczema
MedPage Today) — The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker Eli Lilly announced on Friday. Approval of the injectable interleukin (IL)-13 inhibitor stipulates…
MedPage Today) — The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker Eli Lilly announced on Friday.
Approval of the injectable interleukin (IL)-13 inhibitor stipulates…
Read More
About Author
